Cylindrical reactor with swivel catch in horizontal design. Total volume 7,000l.
Design based on Pressure Equipment Directive 2014/68/EU Cat. IV. Test system in cylindrical design. Double-walled version with pressure connections .
Cyclone in line with good engineering practice. conical casing with tangential inlet nozzle.
Torispherical head, cylindrical wall with dome pressure cover. The tank is equipped with a heating/cooling jacket and insulation cover.
Dear Sir or Madam,
Dear Mr Weinert,
On April 30, 2021, we will open another site at Allergopharma GmbH & Co. KG in Reinbek to support COVID 19 vaccine production in the presence of Federal Minister Spahn and Minister President Günther. We would have been pleased to invite you to this opening.
Unfortunately, this was not possible due to the pandemic.
We would therefore like to take this opportunity to thank you for your extraordinary commitment to supplying equipment at short notice to support vaccine production. Allergopharma, as part of Dermapharm Holding SE, is now a further partner in the Europe-wide production network for the vaccine of BioNTech and Pfizer. This network now comprises more than a dozen important pharmaceutical manufacturers and suppliers. From now on, one of four production steps will take place in Reinbek: the vaccine formulation. This is where our mRNA active ingredient is combined with the lipids. A protective shell is created around the mRNA and the vaccine can reach its target in the body to induce the necessary immune response.
Your company has made a very important contribution to the global pandemic response with great know-how and under incredible time pressure. We would like to express our sincere thanks to you and your team! Without their commitment, the successful completion of the project would not have been possible.
We look forward to working with you in partnership in the future!
Dr. Hans-Georg Feldmeier – CEO Dermapharm SE
Dr. Sierk Poetting – CFO and COO BioNTech SE